glp-1 and autoimmune disease Association between diseases glucagon-like peptide-1 receptor agonists: A real-world evidence study GLP-1 medicines may cut clot-related
Description
Protecting Muscle & Bone Health While on GLP-1 (semaglutide or tirzepatide) Therapy Protein Protect against sarcopenia Target 1.01.2 g/kg/day (e.g., 7090 g for a 75-kg adult)
The biggest checkpoint is pharmacy submission
The medication's use for weight management in competitive sports may raise ethical questions separate from formal prohibition
Ethics Approval: Not Applicable
Furthermore, the study found no increased risk of hospitalization for side effects like diabetic ketoacidosis or severe hypoglycemia, suggesting that GLP-1RAs may represent a promising adjunctive therapy warranting further study in T1D management
